Results 31 to 40 of about 6,163 (183)

Calreticulin enhances B2 bradykinin receptor maturation and heterodimerization [PDF]

Biochemical and Biophysical Research Communications, 2009
In different native tissues and cells the receptor for the vasodepressor bradykinin, B(2), forms dimers with the receptor for the vasopressor angiotensin II, AT(1). Because AT(1)/B(2) heterodimers may contribute to enhanced angiotensin II-stimulated signaling under pathophysiological conditions, we analyzed mechanisms of AT(1)/B(2) heterodimerization ...
Abd Alla, J, Reeck, K, Langer, A, Streichert, T, Quitterer, U   +4 more
openaire   +3 more sources

Bradykinin and its role in osteoarthritis

Reumatismo, 2013
Osteoarthritis (OA), the most common joint disorder, is a disease involving all the articular structures. It presents both degenerative and inflammatory aspects. Recently, the important role of Bradykinin (BK), a phlogistic mediator, has been proposed in
L. De Falco, A. Fioravanti, M. Galeazzi, S. Tenti   +3 more
doaj   +1 more source

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Allergy, Asthma & Clinical Immunology, 2021
Background The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B2 receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) attacks.
Mar Guilarte, Anna Sala-Cunill, María Luisa Baeza, Rosario Cabañas, María Dolores Hernández, Ethel Ibañez, Carlos Hernando de Larramendi, Ramon Lleonart, Teófilo Lobera, Luis Marqués, Blanca Sáenz de San Pedro, Jaco Botha, Irmgard Andresen, Teresa Caballero, for the IOS Study Group   +14 more
doaj   +1 more source

Real‐World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post‐Marketing Surveillance in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Hereditary angioedema (HAE) is a rare, autosomal dominant, life‐threatening disease characterized by recurrent attacks of swelling of the face, upper airway, gastrointestinal tract, limbs, and/or genitalia. Genetic mutations of the SERPING1 gene encoding the C1‐inhibitor (C1‐INH) plasma protein are associated with HAE‐C1INH.
Kumiko Hosono, Miyako Hoshino
wiley   +1 more source

Portal hypertensive response to kinin

Anais da Academia Brasileira de Ciências, 2009
Portal hypertension is the most common complication of chronic liver diseases, such as cirrhosis. The increased intrahepatic vascular resistance seen in hepatic disease is due to changes in cellular architecture and active contraction of stellate cells ...
Maria Kouyoumdjian, Marcia R. Nagaoka, Mauricio R. Loureiro-Silva, Durval R. Borges   +3 more
doaj   +1 more source

Evolutionary Mechanisms of Coagulation Factors in Cetaceans During Aquatic Adaptation

Integrative Zoology, EarlyView.
Compared with Bos taurus, T. truncatus showed shorter prothrombin time and thrombin time but prolonged activated partial thromboplastin time, indicating pathway‐specific remodeling of coagulation. Evolutionary analyses identified 18 positively selected genes and accelerated F11 evolution, while functional assays revealed increased coagulation factor ...
Wenjun Lv, Wanfei Deng, Fei Deng, Shixia Xu, Wenhua Ren   +4 more
wiley   +1 more source

Kininase I drives angiotensin II‐induced hypertension through activation of the bradykinin B1 receptor

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Kininase I, comprising carboxypeptidase N (CPN) and carboxypeptidase M, regulates kinin activity and is up‐regulated during injury, inflammation and immune activation. Under these conditions, kininase I converts bradykinin and kallidin into des‐Arg kinins, primary endogenous agonists of the bradykinin B1 receptor (R ...
Acacia White, Drew Theobald, Alexandra Johnston, David A. Tulis, Johanna Hannan, Srinivas Sriramula   +5 more
wiley   +1 more source

Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply

Trials, 2009
A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc.
Shakur Haleema, Roberts Ian
doaj   +1 more source

Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?

Iranian Journal of Allergy, Asthma and Immunology, 2020
The new virus SARS-CoV-2 is savagely spreading out over the world. The biologic studies show that the target receptor for the virus might be angiotensin-converting enzyme 2 (ACE2). This peptide is responsible for converting angiotensin II (Ang II), which
Seyed-Mohammad Ghahestani, Javad Mahmoudi, Sakineh Hajebrahimi, Amir-Babak Sioofy-Khojine, Hanieh Salehi-Pourmehr, Fatemeh Sadeghi-Ghyassi, Hadi Mostafaei   +6 more
doaj   +1 more source

Angiotensin‐converting enzyme and exercise adaptations: Genetic variability, pharmacological modulation and future directions

The Journal of Physiology, EarlyView.
Abstract figure legend ACE I/D genotype, enzyme activity and integrated physiological adaptations. Upper panel: Conceptual framework linking the ACE I/D polymorphism (left) with circulating/tissue ACE activity (centre; violin plots based on hypothetical data for illustration) and strength/power versus endurance phenotypes (right).
Tórur Sjúrðarson, Nikolai B. Nordsborg   +1 more
wiley   +1 more source